Yesterday, Feb. 11, 2016, 59 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $190.35 to $8,939,553.07.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 697 shares at $5.04 on Feb. 11, 2016. Following this transaction, the SVP, International owned 58,379 shares meaning that the stake was reduced by 1.18% with the 697-share transaction.

The shares most recently traded at $5.03, down $0.01, or 0.2% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 4,500
  • 4-Week # shares sold: 22,871
  • 12-Week # shares bought: 4,500
  • 12-Week # shares sold: 35,092
  • 24-Week # shares bought: 13,500
  • 24-Week # shares sold: 81,898

The average volume for GenMark Diagnostics has been 214,400 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $213.9 million and is part of the health care sector and health services industry. Shares are down 35.05% year-to-date as of the close of trading on Wednesday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ensign Group (ENSG) - FREE Research Report

Keetch Chad, who is Executive Vice President at Ensign Group, sold 359 shares at $19.64 on Feb. 11, 2016. Following this transaction, the Executive Vice President owned 29,179 shares meaning that the stake was reduced by 1.22% with the 359-share transaction.

The shares most recently traded at $18.51, down $1.13, or 6.13% since the insider transaction. Historical insider transactions for Ensign Group go as follows:

  • 4-Week # shares sold: 7,956
  • 12-Week # shares sold: 15,522
  • 24-Week # shares sold: 16,633

The average volume for Ensign Group has been 281,100 shares per day over the past 30 days. Ensign Group has a market cap of $1.0 billion and is part of the health care sector and health services industry. Shares are down 18.03% year-to-date as of the close of trading on Thursday.

The Ensign Group, Inc., through its subsidiaries, provides skilled nursing and rehabilitative care services in the United States. It operates through two segments, Transitional, Skilled and Assisted Living Services; and Home Health and Hospice Services. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 19.0. Currently, there are 5 analysts who rate Ensign Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENSG - FREE

TheStreet Quant Ratings

rates Ensign Group as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Ensign Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Usana Health (USNA) - FREE Research Report

Gull Global Ltd, who is 10% Owner at Usana Health, sold 10,000 shares at $96.37 on Feb. 11, 2016. Following this transaction, the 10% Owner owned 6.4 million shares meaning that the stake was reduced by 0.16% with the 10,000-share transaction.

The shares most recently traded at $98.06, up $1.69, or 1.73% since the insider transaction. Historical insider transactions for Usana Health go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 26,000
  • 24-Week # shares sold: 53,000

The average volume for Usana Health has been 129,000 shares per day over the past 30 days. Usana Health has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are down 25.78% year-to-date as of the close of trading on Wednesday.

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease worldwide. The company has a P/E ratio of 17.1. Currently, there is 1 analyst who rates Usana Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USNA - FREE

TheStreet Quant Ratings

rates Usana Health as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Usana Health Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.